Retirement Systems of Alabama Has $6.58 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Retirement Systems of Alabama lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,567 shares of the medical device company’s stock after selling 2,184 shares during the period. Retirement Systems of Alabama’s holdings in DexCom were worth $6,577,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of DXCM. Crossmark Global Holdings Inc. grew its stake in DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after purchasing an additional 182 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its holdings in shares of DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after buying an additional 185 shares during the last quarter. Magnolia Capital Advisors LLC grew its stake in shares of DexCom by 2.6% in the 4th quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock valued at $638,000 after buying an additional 210 shares in the last quarter. Riverview Trust Co increased its holdings in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its position in DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 265 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 42,342 shares of company stock valued at $3,628,069. Corporate insiders own 0.30% of the company’s stock.

DexCom Stock Performance

DXCM opened at $88.08 on Monday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a market cap of $34.40 billion, a price-to-earnings ratio of 52.74, a PEG ratio of 2.26 and a beta of 1.14. The company’s fifty day moving average price is $81.76 and its two-hundred day moving average price is $75.36. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DXCM. Oppenheimer decreased their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Citigroup upped their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and raised their price objective for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Leerink Partners reduced their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $98.41.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.